Program
zanidatamab
Also written as “Zanidatamab” and “ZW25 (Zanidatamab)”.
Its studies are mostly in Breast Neoplasms · Biliary Tract Neoplasms · Stomach Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 105 open or running | phase 3since Nov 5, 2021 | Aug 23, 2016 | Dec 31, 2026phase 2 · NCT06695845 |
| BeOne Medicines | 10 open or running | phase 3since Nov 14, 2019 | Nov 14, 2019 | none ahead |
Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited and alx-oncology-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2016First study: phase 1 study in Breast NeoplasmsNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT02892123 · 279 enrolled · United States, Canada, Korea, Republic of
- Feb 22, 2019Phase 2 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT03929666 · 74 enrolled · United States, Canada, Chile and more
- Nov 14, 2019BeOne Medicines's first study: phase 3 study in Advanced MalignanciesNew to BeOne MedicinesBeOne Medicines · NCT04164199 · 404 enrolled · United States, Australia, China and more
- Jan 7, 2020Phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT04224272 · 51 enrolled · United States, Canada, Spain
- Jul 6, 2020Phase 2 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT04466891 · 87 enrolled · United States, Canada, Chile and more
- Aug 23, 2021Phase 2 study in HER2-expressing CancersJazz Pharmaceuticals · NCT05027139 · 52 enrolled · United States
- Nov 5, 2021Phase 3 study in Stomach NeoplasmsJazz Pharmaceuticals · NCT05152147 · 920 enrolled · Argentina, Australia, Belgium and more
- Feb 21, 2024Phase 3 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT06282575 · 286 planned · United States, Argentina, Belgium and more
- May 24, 2024Phase 3 study in Metastatic HER2-positive Breast CancerJazz Pharmaceuticals · NCT06435429 · 550 planned · United States, Australia, Austria and more
- Nov 16, 2024Phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT06695845 · 200 planned · United States, Georgia, South Korea and more
- Jul 28, 2025Phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT07102381 · 125 planned · United States, Germany, Italy and more
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT06695845
- Dec 29, 2027Primary completion: phase 2 study in Breast NeoplasmsJazz Pharmaceuticals · NCT07102381
- Apr 28, 2028Primary completion: phase 3 study in Metastatic HER2-positive Breast CancerJazz Pharmaceuticals · NCT06435429
- Dec 1, 2028Primary completion: phase 3 study in Biliary Tract NeoplasmsJazz Pharmaceuticals · NCT06282575
TargetBeta
“An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07102381Breast Neoplasms · United States, Germany, Italy and more | 2 | Recruiting | Jazz Pharmaceuticals | Dec 29, 2027 | 125 |
| NCT06695845Breast Neoplasms · United States, Georgia, South Korea and more | 2 | Recruiting | Jazz Pharmaceuticals | Dec 31, 2026 | 200 |
| NCT06435429Metastatic HER2-positive Breast Cancer · United States, Australia, Austria and more | 3 | Recruiting | Jazz Pharmaceuticals | Apr 28, 2028 | 550 |
| NCT06282575Biliary Tract Neoplasms · United States, Argentina, Belgium and more | 3 | Recruiting | Jazz Pharmaceuticals | Dec 1, 2028 | 286 |
| NCT05152147Stomach Neoplasms · Argentina, Australia, Belgium and more | 3 | Active, not recruiting | Jazz Pharmaceuticals | Jul 15, 2026 | 920 |
| NCT05027139HER2-expressing Cancers · United States | 2 | Completed | Jazz Pharmaceuticals | Aug 29, 2025 | 52 |
| NCT04466891Biliary Tract Neoplasms · United States, Canada, Chile and more | 2 | Completed | Jazz Pharmaceuticals | Jul 28, 2023 | 87 |
| NCT04224272Breast Neoplasms · United States, Canada, Spain | 2 | Completed | Jazz Pharmaceuticals | Apr 28, 2023 | 51 |
| NCT04164199Advanced Malignancies · United States, Australia, China and more | 3 | Completed | BeOne Medicines | May 23, 2026 | 404 |
| NCT03929666Biliary Tract Neoplasms · United States, Canada, Chile and more | 2 | Completed | Jazz Pharmaceuticals | Aug 30, 2025 | 74 |
| NCT02892123Breast Neoplasms · United States, Canada, Korea, Republic of | 1 | Completed | Jazz Pharmaceuticals | Oct 31, 2024 | 279 |
How it is read
Names in the registry
- “Zanidatamab”, 7 entries
- “ZW25 (Zanidatamab)”, 4 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 5 studies
- Biliary Tract Neoplasms, 3 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.